Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is intend to improve the objective response rate in treatment of camrelizumab in
recurrent primary central nervous system lymphoma patients.